Equivalency of Fecal Immunochemical Tests and Colonoscopy in Familial Colorectal Cancer Screening

Quintero, Enrique; Carrillo, Marta; Gimeno–García, Antonio Z.; Hernández‐Guerra, Manuel; Nicolás–Pérez, David; Alonso‐Abreu, Inmaculada; Díez-Fuentes, María Luisa; Abraira, Víctor

doi:10.1053/j.gastro.2014.08.004

Cited by 56 publications

(56 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a randomized controlled trial, there was a nonsignifi cant trend toward detection of more advanced neoplasia in subjects with a positive family history who underwent colonoscopy compared with FIT ( 126 ). Th us, patients with a positive family history who decline colonoscopy should be off ered FIT screening ( 126 ).…”

Section: Family History Of Crc and Polypsmentioning

confidence: 99%

Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer

Rex

Boland

Dominitz

et al. 2017

American Journal of Gastroenterology

530

266

View full text Add to dashboard Cite

Section: Family History Of Crc and Polypsmentioning

confidence: 99%

Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer

Rex

Boland

Dominitz

et al. 2017

American Journal of Gastroenterology

530

266

View full text Add to dashboard Cite

“…Finally, a randomized, controlled trial comparing FIT with colonoscopy has shown that FIT plus colonoscopy when positive has a similar efficacy as direct colonoscopy to detect AN in FDRs of patients with CRC. 13 Based on these published results, we designed a cohort study aimed at comparing the diagnostic accuracy of FIT to detect AN on familial and average-risk CRC screening. We hypothesized that FIT overall accuracy to detect AN is similar between both cohorts.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic accuracy of fecal immunochemical test in average‐ and familial‐risk colorectal cancer screening

et al. 2014

View full text Add to dashboard Cite

Background: There is little information about the fecal immunochemical test (FIT) in familial-risk colorectal cancer (CRC) screening. Objectives: The objective of this article is to investigate whether FIT diagnostic accuracy for advanced neoplasia (AN) differs between average and familial-risk (first-degree relative) patients. Methods: A total of 1317 consecutive participants (595 familial) who collected one stool sample before performing a colonoscopy as a CRC screening test were included. FIT diagnostic accuracy for AN was evaluated with Chi-square test at a 20 mg hemoglobin/g of feces cut-off value. Finally, we determined which variables were independently related to AN. Results: An AN was found in 151 (11.5%) patients. The overall accuracy was not statistically different between both cohorts for AN (88.4%, 91.7%; p ¼ 0.051). At the cut-off stablished, differences in FIT sensitivity (31.1%, 40.6%; p ¼ 0.2) or specificity (96.5%, 97.3%; p ¼ 0.1) were not statistically significant. Finally, independent variables such as sex (male) (odds ratio (OR) 2.1, 95% confidence interval (CI) 1.4-3.1), age (50-65, >65 years) (OR 2.1, 95% CI 1.1-4.3; OR 2.7, 95% CI 1.2-6.1), previous colonoscopy (OR 0.4, 95% CI 0.2-0.9) and FIT 20 mg/g feces (OR 17.7, 95% CI 10.8-29.1) were associated with AN diagnosis. Conclusions: FIT accuracy for AN detection is equivalent in average and familial-risk CRC screening cohorts.

show abstract

“…Unfortunately, no investigation detecting both ADA and CRC in FDRs of CRC patients similar to that of a single colonoscopy [51] . Thus, FIT could increase screening acceptability in high-risk subjects and reduce the number of negative screening colonoscopy results [51] . The disadvantage of FIT is the cost, even if it is now approaching that of gFOBT, particularly for qualitative tests [52] .…”

Section: Familial Crc Screening: What To Domentioning

confidence: 99%

Familial colorectal cancer screening: When and what to do?

Blanco¹,

Paoluzi²,

Sileri³

et al. 2015

WJG

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third leading cause of death worldwide and represents a clinical challenge. Family members of patients affected by CRC have an increased risk of CRC development. In these individuals, screening is strongly recommended and should be started earlier than in the population with average risk, in order to detect neoplastic precursors, such as adenoma, advanced adenoma, and nonpolypoid adenomatous lesions of the colon. Fecal occult blood test (FOBT) is a non invasive, widespread screening method that can reduce CRC-related mortality. Sigmoidoscopy, alone or in addition to FOBT, represents another screening strategy that reduces CRC mortality. Colonoscopy is the best choice for screening highrisk populations, as it allows simultaneous detection and removal of preneoplastic lesions. The choice of test depends on local health policy and varies among countries. Core tip: One-fifth of people who develop colorectal cancer (CRC) have a first-degree relative (FDR) affected by this malignancy. Screening is an efficient method to reduce mortality for CRC and should be started in FDRs earlier than in the population at average risk. There is a large disparity in guidelines for screening in familial CRC, therefore, here we address the principal indication and methods for screening in this population at increased risk. Recent or emerging methods to improve the participation rate in screening programs are described. Ongoing trials on CRC screening are also reported.

show abstract

Equivalency of Fecal Immunochemical Tests and Colonoscopy in Familial Colorectal Cancer Screening

Cited by 56 publications

References 42 publications

Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer

Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer

Diagnostic accuracy of fecal immunochemical test in average‐ and familial‐risk colorectal cancer screening

Familial colorectal cancer screening: When and what to do?

Contact Info

Product

Resources

About